MSB 4.00% $1.17 mesoblast limited

MSB Trading 2020 - a new dawn, page-12216

  1. 6,929 Posts.
    lightbulb Created with Sketch. 1521
    Congratulations Mesoblast on reaching your primary endpoint in CHF trial. Looking at the data there were less events requiring hospitalisation for the control group due to the participants dying! Fantastic result SAID NO ONE EVER! eek.png

    good luck to long term SHs who actually understand the company they have invested in. My medical knowledge extends to bandaids & paracetamol but my knowledge of number helps me understanf that 60% reduction in mortality is waaaaay superior to current best standard of care! And the fact that Rexlemestocel-L is an add-on to care, just makes the commercialisation deal even sweeter!

    HODL!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.